Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models

  • Antonelli, Roberta|||0000-0001-6884-7847
  • Jiménez Jiménez, Carlos|||0000-0001-9219-3492
  • Riley, Misha
  • Servidei, Tiziana|||0000-0003-0529-7686
  • Riccardi, Riccardo
  • Soriano, Aroa|||0000-0001-9659-1471
  • Roma, Josep|||0000-0001-7692-6123
  • Martinez-Saez, Elena|||0000-0001-6004-5364
  • Martini, Maurizio|||0000-0002-6260-6310
  • Ruggiero, Antonio|||0000-0002-6052-3511
  • Moreno Martin Retortillo, Lucas|||0000-0002-0708-1670
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Gallego, Soledad|||0000-0002-4712-9624
  • Bové, Jordi|||0000-0002-2529-205X
  • Hooker, Jacob M.
  • Segura, Miguel F.|||0000-0003-0916-3618
Pediatric ependymoma (EPN) is a highly aggressive tumor of the central nervous system that remains incurable in 40% of cases. In children, the majority of cases develop in the posterior fossa and can be classified into two distinct molecular entities: EPN posterior fossa A (PF-EPN-A) and EPN posterior fossa B (PF-EPN-B). Patients with PF-EPN-A have poor outcome and are in demand of new therapies. In general, PF-EPN-A tumors show a balanced chromosome copy number profile and have no recurrent somatic nucleotide variants. However, these tumors present abundant epigenetic deregulations, thereby suggesting that epigenetic therapies could provide new opportunities for PF-EPN-A patients. In vitro epigenetic drug screening of 11 compounds showed that histone deacetylase inhibitors (HDACi) had the highest anti-proliferative activity in two PF-EPN-A patient-derived cell lines. Further screening of 5 new brain-penetrating HDACi showed that CN133 induced apoptosis in vitro, reduced tumor growth in vivo and significantly extended the survival of mice with orthotopically-implanted EPN tumors by modulation of the unfolded protein response, PI3K/Akt/mTOR signaling, and apoptotic pathways among others. In summary, our results provide solid preclinical evidence for the use of CN133 as a new therapeutic agent against PF-EPN-A tumors.